RxDoctor Payments Data

Rachel Huynh

Psychiatric/Mental Health · Fort Smith, ARNPI 1598328163

Payments from drug & device makers

$2,064in general payments, 2019–2025

Across 136 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$658
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$315
  • Alkermes, Inc.$217
  • Lundbeck LLC$167
  • Johnson & Johnson$121
  • Otsuka America Pharmaceutical, Inc.$101
  • plus $485 from 11 others

What the payments were for

  • Food & beverage$2,064100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,064 in reported general payments places this provider in the 70th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$7,337
Medicare patients
29
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl29$38,503
TrintellixVortioxetine Hydrobromide31$15,018
Aripiprazole20$1,515
Vilazodone Hcl12$1,047
Venlafaxine Hcl ErVenlafaxine Hcl69$924
Bupropion XlBupropion Hcl58$723
Duloxetine Hcl61$697
Clonazepam67$572
Mirtazapine53$553
Buspirone Hcl52$453
Quetiapine Fumarate38$423
Lamotrigine60$371
Olanzapine35$358
Hydroxyzine Pamoate26$350
Sertraline Hcl69$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$658$38,50329 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$46$15,01831 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Fort Smith

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →